Colimune-Oral (Canada)This page contains information on Colimune-Oral for veterinary use.
The information provided typically includes the following:
- Colimune-Oral Indications
- Warnings and cautions for Colimune-Oral
- Direction and dosage information for Colimune-Oral
Colimune-oralThis treatment applies to the following species:
Escherichia coli Polyclonal Antibodies (Equine Origin)
For Veterinary Use Only
As an aid in the reduction of fatal calf scours due to infections with enteropathogenic K99 E. coli organisms.
The polyclonal antibodies in COLIMUNE®-ORAL are produced from a selected strain of enteropathogenic K99 E. coli (EPEC).
COLIMUNE®-ORAL offers an alternative to immunized dam colostrum as a means of delivering EPEC antibodies to the small intestines of newborn animals. K99 pilus antigen is frequently associated with enterotoxigenic strains of E. coli isolated from the intestines of calves, sheep and pigs.(1,2,3,4) Pilus antigens have been shown to be the main attachment mechanism whereby EPEC attach to, and colonize the small intestines of neonatal animals. Any mechanism which will interfere with this attachment and colonization process is capable of preventing the clinical entity of neonatal diarrhea.(5) It has been shown in a number of vaccination trials that passive K99 pilus antibodies within the lumen of the small intestines will prevent severe, fatal, enterotoxigenic colibacillosis.(6,7,8,9,10) In these studies, the passive antibodies were introduced to the small intestines of suckling animals via the colostrum from previously immunized dams.
Mode Of ActionThe 12 hour period post partum is the most critical in terms of preventing piliated enteropathogenic E. coli from adhering to the intestinal villi. COLIMUNE®-ORAL contains antibodies against K99 pilus antigens. As long as these antibodies are present in the intestines during the critical period, they are capable of reducing the intestinal colonization, diarrhea and mortality associated with K99 EPEC infections.
Colimune-Oral Dosage And AdministrationAdminister ORALLY to the newborn calf within the first 12 hours of life. Syringe: administer the entire contents of one 10 mL syringe orally. Vial: withdraw one dose (10 mL) from the 100 mL vial by use of a sterile needle and syringe. Remove needle from syringe to administer 10 mL oral dose.
Safety And EfficacyIn a challenge study using a homologous organism, where only 1 of 9 of the colostrum-deprived controls survived, COLIMUNE®-ORAL protected 8 of 10 of the treated calves. Field trial safety testing has not shown any adverse reaction. COLIMUNE®-ORAL may be administered to calves regardless of other agents that may already have been given to the calf or its dam.
1. Store product at 2-7°C (36-45°F). Do not freeze.
2. Syringes must be kept sealed until the time of use.
3. Use entire contents of the syringe when first opened. Do not save partial contents.
4. Burn empty containers and unused portions.
5. Phenol, thimerosal and oxytetracycline are added as preservatives.
Calfhood diarrhea is a complex disorder with many possible contributing causes. COLIMUNE®-ORAL may not reduce mortality when scours are caused by, or complicated by, parasites, viruses, nutritional factors, management practices, or other bacteria.
1. Orskov I., Orskov F., Smith HW., et al: The establishment of K99, of thermolabile transmissible Escherichia coli K antigen, previously called “Kco” possessed by calf and lamb enteropathogenic strains. Acta Pathol Microbiol Scand (B) 83:31-36, 1975.
2. Moon HW., Whip SC., Skartvedt SN.: Etiologic diagnosis of diarrheal diseases of calves: Frequency and methods for detecting enterotoxin and K99 antigen production by Escherichia coli. AM J Vet Res 37: 1025-1029, 1976.
3. Guinee PAM., Jansen WH.: Detection of enterotoxigenicity and attachment factors in Escherichia coli strains of human, porcine and bovine origin; The comparative study. Zentralbl Bakteriol (A) 243: 245-257, 1979.
4. Moon HW., Nagy B., Isaacson RE., et al: Occurrence of K99 antigen on Escherichia coli isolated from pigs and colonization of pig ileum by K99+ enterotoxigenic E. coli from calves and pigs. Infect Immun 15:614-620, 1977.
5. Smith HW., Huggins MB.: The influence of plasmid-determined and other characteristics of enteropathogenic Escherichia coli on their ability to proliferate in the alimentary tract of piglets, calves and lambs. J Med Microbiol 11:471-492, 1978.
6. Acres SD., Isaacson RE., Babiuk LA., et al: Immunization of calves against enterotoxigenic colibacillosis by vaccinating dams with purified K99 antigen and whole cell bacterins. Infect Immun 25: 121-126, 1979.
7. Contrepoi SM., Girardeau JP., Dubourguier HC., et al: Specific protection by colostrum from cows vaccinated with the K99 antigen in newborn calves experimentally infected with E.coli+ and K99+. Ann Res Vet 9:385-388, 1978.
8. Morris JA., Wray C., Sojka WJ.: Passive protection of lambs against enteropathogenic Escherichia coli: Role of antibodies and serum in colostrum of dams vaccinated with K99 antigen. J Med Microbiol 13: 265-271, 1980.
9. Nagy B.: Vaccination of cows with K99 extract to protect newborn calves against experimental enterotoxigenic colibacillosis. Infect Immun 27: 21-24, 1980.
10. Sojka WJ., Wray C., Morris JA.: Passive protection of lambs against experimental enteric colibacillosis by colostral transfer of antibodies from K99 vaccinated ewes. J Med Microbiol 11: 493-499, 1978.
PACKAGING: COLIMUNE®-ORAL is available in 10 x 10 mL syringes (10 doses).
BIONICHE ANIMAL HEALTH CANADA INC., P.O. Box 1570, Belleville, Ontario K8N 5J2, A Division of Bioniche Life Sciences Inc.
Canadian Veterinary Biologics Establishment Licence No.8
BIONICHE FOOD SAFETY
P.O. BOX 1570, 231 DUNDAS ST. E., BELLEVILLE, ON, K8N 5J2
|Every effort has been made to ensure the accuracy of the Colimune-Oral information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2013 North American Compendiums. Updated: 2013-09-18